



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

Mail Stop 6010

June 25, 2008

Larry Bullock
Chief Financial Officer
BioMimetic Therapeutics, Inc.
389-A Nichol Mill Lane
Franklin, TN 37067

RE: BioMimetic Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2007
File No. 000-51934

Dear Mr. Bullock:

We have completed our review of your Form 10-K and related filings and have no further comments at this time.

Sincerely,

Brian Cascio
Branch Chief